Tuesday, June 19, 2018
 
 
Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics
 
(February 14, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:USA,Medicine,Surgery,Surgery,Medication,Science,Medical,Biology,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Suomen Hoivatilat Oyj: New business concepts
  • Global 3D Medical Imaging Industry
  • Michael A. Smith, MD promoted to director of education at Life Extension
  • Cardiac Pacemaker Market to be Worth US$ 11.1 Billion by 2026
  • Global Cosmetic Antioxidants Market Forecast to 2023: Market is Driven by a Rise in Aging Population, Increasing Disposable Income, and Changing Lifestyle

    Cancer
  • Celyad Doses First AML Patient at Final Dose Level in CYAD-01 THINK Trial and Begins Dosing First Patient With Second Cycle of Therapy
  • Yoichiro Ito, MD, Recognized for Development of Cancer Chemical Separation Method
  • Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark
  • Avantis Medical Names Matt Frushell as President and CEO, Salmaan Hameed as CTO, as Company Moves to Full Commercial Operation
  • Pharmaceutical Glass Packaging Market Worth $22.05 Billion by 2025: Grand View Research, Inc.
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines